Canada: Canadian Patent Term Extension - Bill Is In The House

Last Updated: November 10 2016
Article by Noel Courage

Canada and Europe finally signed off on the Comprehensive Economic and Trade Agreement ("CETA"). Its most significant aspect for the pharma industry is prospect of increased drug patent terms by up to 2 years. Not long after the ink was dry on CETA, an amendment (implementation) Bill was introduced into Canadian Parliament on October 31, 2016. This Bill is the first concrete domestic legislative step toward becoming a law1.

Background on CETA

CETA was the product of several years of negotiations. It is a wide-ranging trade agreement covering diverse topics such as foreign ownership and investments, access to public procurement contracts, automobiles, food (e.g. beef and dairy products) and agriculture. Pharmaceuticals were also a prominent part of the discussion.

Patent Term Extension - Supplementary Protection Certificate

Patents give companies the exclusive right to use an invention for a time period, typically up to 20 years from the patent filing date. A maximum two years of additional patent rights for an approved drug will be available by way of a Supplementary Protection Certificate ("SPC")2. The proposed Canadian SPC system is based on the European SPC system. It provides the same practical effect as as a patent term extension, but the additional patent protection is effected by the SPC. The SPC is limited to the particular medicine that is an approved drug (for example, if the patent covers non-commercialized drugs, the non-commercialized drugs will not be protected further). The additional SPC patent protection will be capped at a maximum of 2 years, as discussed in more detail below.

What drugs and patents qualify?

Eligible drugs are defined broadly to include human and veterinary drugs3. This article will focus on human SPC issues. If the same drug is useful for both purposes, they are to be treated as different drugs for purposes of the SPC rules4. Variants of a drug will be treated the same (ie. only one SPC, per drug)5. Reissued patents are also eligible for an SPC6.

The SPC is available upon request of the brand name company, for a patent filed on or after October 1, 19897. The patent will have to pertain to a medicinal ingredient, or a combo, that was authorized after a cut-off date to be set by government8. Drugs approved for sale in Canada prior to this cut-off date will not be eligible to apply for a SPC. The SPC is only available where the drug is being approved by Health Canada (Canada's equivalent of the US FDA) for the first time9. There will be no stacking of multiple SPC's – one SPC for one patent per drug.

The SPC Application Process

The main deadline to file an application for SPC protection will be based on a time period to be set by government regulation in future10. The time period will start to run on the day that Canadian marketing authorization is granted by Health Canada (assuming the patent is granted on that date; otherwise, the time period will start to run later, from the date of patent grant).

To qualify for the SPC, there also appears to be a limited time period to file a new drug submission in Canada after filing a corresponding drug submission is filed in certain other countries11. This time period will start to run from the date of filing of the corresponding foreign new drug submission. This is intended to encourage companies to promptly file a new drug submission in Canada. It also appears to be a risk for companies to lose the option for Canadian SPC protection, by not paying attention to the timing requirements.

Where there are multiple patents, the brand name company has the flexibility to select the benefiting patent for the drug. Only one patent can be the subject of an SPC12. Eligible patents will include one or more claims, such as to a product per se (ie. active ingredient alone or in a combination), a process to obtain a product or the use of a product (eg. medical treatment)13.

The SPC Rights and Term

The SPC will set out the patent number, identify the drug, as well as the starting and end dates of the SPC protection. It takes effect after the patent expiry date. The term is for a maximum of two years, but may be shorter depending on the patent issue date and how quickly regulatory review proceeded at Health Canada14. Health Canada may shorten the SPC term if it believes that the Applicant delayed getting its marketing authorization to try to increase SPC term. Price regulation will continue to apply during the SPC term15.

The usual exceptions to infringement for work relating to development of information for a regulatory submission continue to apply. There is an additional exception to infringement for generic drugs to be exported, which was a carve-out promised by Canada to benefit its generic drug industry16.

The SPC is transferrable along with the corresponding whole or a part of the patent.

SPC is presumed valid in litigation17. An SPC infringement action may be brought in the same manner as a patent infringement action18. If the underlying patent is found invalid in court, the SPC is also void19. The Federal Court of Canada has jurisdiction to rule an SPC void20.

Next Steps

The Bill goes through additional readings in the House of Parliament before it is passed as a law and comes into force. There are likely to be some edits to the Bill along the way, though the substance of the SPC itself is unlikely to change much. There are still a number of important gaps to be filled in by regulators relating to timelines and other issues, and we will provide updates on those issues in future.

Click here for our article on changes to patent litigation under the Bill.


1 Bill C-30, An Act to implement the Comprehensive Economic and Trade Agreement between Canada and the European Union and its Member States and to provide for certain other measures, First Session, Forty-second Parliament,64-65 Elizabeth II, 2015-2016 (first reading October 31, 2016).

2 These new rules will are in s. 50 of the amending Act. They are currently intended to be inserted in the Patent Act as Sections 104 onward. The SPC grant is enabled by s.110.

3 "drug" drug means a substance or a mixture of substances manufactured, sold or represented for use in 15

(a) the diagnosis, treatment, mitigation or prevention of a disease, disorder or abnormal physical state, or its

symptoms, in human beings or animals; or (b) restoring, correcting or modifying organic functions in human beings or animals.

4 S.105(2).

5 S. 105(5).

6 S. 47(1.1), s.105(1).

7 S.106(b).

8 S.106(c).

9 S.106(d).

10 S.106(3).

11 S. 106(f). The other countries will be identified by future regulation.

12 S. 106(6). There is also a process to resolve competing claims for an SPC.

13 S. 124. Regulation will set out the categories of patents more specifically, but prior government guidance indicated it will include at least those noted in this article.

14 The SPC term is calculated by subtracting five years from the patent application filing date and ending on the date of the Health Canada marketing authorization (two years maxium). To get an SPC, the calculation must not produce a zero or negative value.

15 See the Bill starting at s.46.

16 S.115(2).

17 S.116(1).

18 S.124.

19 S.125.

20 S.110(1). See also s. 128 of the Bill re amendments to the Federal Courts Act to give the FCC jurisidiction over SPC issues generally.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions